Evidence map›Paper›PMID 32212015›Full record

ArticleJournal of neural transmission (Vienna, Austria : 1996)2020

The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients.

Angelo Antonini, Giovanni Abbruzzese, Alfredo Berardelli, Nicola Modugno, Italo Stroppa, Filippo Tamma, Mariachiara Sensi, Francesca Mancini, Giovanni Cossu, Alessandro Stefani and 12 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Journal of neural transmission (Vienna, Austria : 1996), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Effects of levodopa/carbidopa intestinal gel infusion on autonomic symptoms in advanced Parkinson's disease: a systematic review.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2025
    Pooled it
  2. Pooled it
  3. Observational
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

Angelo AntoniniParkinson and Movement Disorders Unit, Department of Neuroscience, University of Padua, Padua, Italy. angelo3000@yahoo.com.
Giovanni AbbruzzeseDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal Child Health, IRCCS Ospedale Policlinico San Martino, University of Genoa, Genoa, Italy.
Alfredo BerardelliDepartment of Human Neurosciences, Sapienza University of Rome, IRCCS Neuromed, Rome, Italy.
Nicola ModugnoParkinson Centre, IRCCS Neuromed, Pozzilli, Italy.
Italo StroppaU.O. Dipartimentale di Endoscopia Digestiva Operativa e D'Urgenza, Policlinico Tor Vergata, Rome, Italy.
Filippo TammaNeurology Unit, Miulli Hospital, Acquaviva delle Fonti, BA, Italy.
Mariachiara SensiNeurology Unit, Hospital Sant'Anna, Cona, Ferrara, Italy.
Francesca ManciniUO Neurologia e Stroke Unit e Laboratorio Neuroscienze, Istituto Auxologico San Luca, Milan, Italy.
Giovanni CossuSC Neurologia e Stroke Unit, Azienda Ospedaliera Brotzu, Cagliari, Italy.
Alessandro StefaniUOSD Parkinson, Fondazione Policlinico Tor Vergata, Rome, Italy.
Nicola TambascoNeurology Department, Perugia General Hospital, University of Perugia, Perugia, Italy.
Alessandro TessitoreDepartment of Medical, Surgical, Neurological, Metabolic and Aging Sciences, University of Campania, "Luigi Vanvitelli", Caserta, Italy.
Giovanni FabbriniDepartment of Human Neurosciences, Sapienza University of Rome, IRCCS Neuromed, Rome, Italy.
Francesco E PontieriDepartment NESMOS, Sant'Andrea Hospital, "Sapienza" University, Rome, Italy.
Paolo SollaNeurology Unit, Policlinico Universitario Monserrato, Cagliari, Italy.
Anna Rita BentivoglioInstitute of Neurology, Università Cattolica del Sacro Cuore, Rome, Italy.
Cristoforo ComiNeurology Unit, Parkinson's Disease and Movement Disorders Centre, University of Piemonte Orientale, Novara, Italy.
Brigida MinafraParkinson's Disease and Movement Disorders Unit, IRCCS C. Mondino Foundation, Pavia, Italy.
Giulio RiboldazziNeurology Unit, Parkinson's Disease and Movement Disorders Centre, ASST dei Sette Laghi, Varese, Italy.
Donato MelchiondaS.C. Neurology, Neuroscience Department, A.O.U. Ospedali Riuniti, University of Foggia, Foggia, Italy.
Tommaso MartinoS.C. Neurology, Neuroscience Department, A.O.U. Ospedali Riuniti, University of Foggia, Foggia, Italy.
Leonardo LopianoDepartment of Neuroscience "Rita Levi-Montalcini", University of Torino, Turin, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The TANDEM investigation was carried out in 17 Italian Movement Disorder centers on behalf of a joint initiative of neurologist members of the Italian Academy for Parkinson's disease and Movement Disorders (LIMPE-DISMOV Academy) and gastroenterologist members of the Italian Society of Digestive Endoscopy (SIED) to evaluate the efficacy and tolerability of levodopa-carbidopa intestinal gel (LCIG) in patients with advanced Parkinson's disease (PD) in routine medical care. Motor scores in "ON" and OFF" state (UPDRS-III), complications of therapy (UPDRS-IV), activities of daily living, sleep disorders and quality of life were evaluated at baseline and at two follow-up assessments (FUV1 and FUV2) within the initial 12-month LCIG treatment. In 159 patients (55% males) with a mean age of 69.1 ± 6.6 years and a diagnosis of PD since 13.6 ± 5.5 years, the UPDRS-III total score (in "OFF") decreased from baseline (45.8 ± 13.2) to FUV1 (41.0 ± 17.4; p < 0.001) and FUV2 (40.5 ± 15.5; p < 0.001), the UPDRS-IV total score decreased from baseline (8.8 ± 2.9) to FUV1 (5.1 ± 3.4; p < 0.001) and FUV2 (5.5 ± 3.2; p < 0.001). The percentage of patients exhibiting freezing, dystonia, gait/walking disturbances, falls, pain and sleep disorders was significantly reduced. Twenty-eight device complications were reported and 11 (6.9%) patients prematurely terminated the study. LCIG after 12-month treatment led to sustained improvement of time spent in "OFF", complications of therapy, PD-associated symptoms and sleep disorders. LCIG tolerability was consistent with the established safety profile of LCIG.

Indexed as

CarbidopaParkinson DiseaseActivities of Daily LivingAntiparkinson AgentsDrug CombinationsFemaleGelsHumansInfant, NewbornLevodopaMaleQuality of LifeAntiparkinson AgentsCarbidopaDrug CombinationsGelsLevodopaLevodopa-carbidopa intestinal gelMotor symptomsParkinson’s diseaseQuality of lifeRoutine patient follow-up

Identifiers

PMID32212015

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.